中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2013年
12期
1048-1052
,共5页
肖静%郭佳%赵志红%靳云凤%刘栋%赵占正
肖靜%郭佳%趙誌紅%靳雲鳳%劉棟%趙佔正
초정%곽가%조지홍%근운봉%류동%조점정
腹膜透析%环氧化酶2抑制剂%血管内皮生长因子C%淋巴管生成
腹膜透析%環氧化酶2抑製劑%血管內皮生長因子C%淋巴管生成
복막투석%배양화매2억제제%혈관내피생장인자C%림파관생성
Peritoneal dialysis%Cyclooxygenase 2 inhibitors%Vascular endothelial growth factor C%Lymphangiogenesis
目的 探讨环氧合酶-2 (COX-2)抑制剂(塞来昔布)对尿毒症腹膜透析(腹透)大鼠腹膜淋巴管形成及腹膜功能的影响.方法 检测塞来昔布干预的尿毒症腹透大鼠的腹膜,从腹膜的结构与功能、腹膜组织淋巴管密度(LVD)及COX-2、血管内皮生长因子-C(VEGF-C)、淋巴管内皮透明质酸受体-1(LYVE-1)mRNA及蛋白表达水平,观察塞来昔布对尿毒症腹透大鼠腹膜淋巴管形成及腹膜功能的影响.结果 随着透析时间的延长,尿毒症大鼠腹膜厚度增加,炎性细胞浸润明显,腹膜平衡试验(PET)显示超滤量明显下降,葡萄糖转运量上升,但塞来昔布干预组可提高超滤量,减少葡萄糖转运量(P<0.05).5组动物的腹膜组织LVD及COX-2、VEGF-C、LYVE-1 mRNA和蛋白表达的检测发现:与正常组相比,尿毒症组和腹透组均明显升高(P<0.05);而腹透+塞来昔布干预组较腹透组均明显降低(P<0.05).相关性分析显示,腹透组蛋白水平上COX-2的表达量与LVD(r=0.847,P<0.05)、VEGF-C(r =0.910,P<0.05)呈正相关,VEGF-C的表达量与LVD呈正相关(r=0.975,P<0.05).腹透+塞来昔布干预组蛋白水平上COX-2的表达量与LVD(r=0.970,P<0.05)、VEGF-C(r =0.927,P<0.05)呈正相关,VEGF-C的表达量与LVD呈正相关(r=0.919,P<0.05).结论 大鼠体内高糖透析液与尿毒症环境的刺激可以促进腹膜组织COX-2、VEGF-C、LYVE-1基因和蛋白的表达水平上调及新生淋巴管数量增多.COX-2抑制剂可缓解长期腹透导致的腹膜组织形态结构和功能的改变,并能抑制新生淋巴管的形成,可能是通过COX-2依赖的途径下调VEGF-C的产生而发挥作用的.
目的 探討環氧閤酶-2 (COX-2)抑製劑(塞來昔佈)對尿毒癥腹膜透析(腹透)大鼠腹膜淋巴管形成及腹膜功能的影響.方法 檢測塞來昔佈榦預的尿毒癥腹透大鼠的腹膜,從腹膜的結構與功能、腹膜組織淋巴管密度(LVD)及COX-2、血管內皮生長因子-C(VEGF-C)、淋巴管內皮透明質痠受體-1(LYVE-1)mRNA及蛋白錶達水平,觀察塞來昔佈對尿毒癥腹透大鼠腹膜淋巴管形成及腹膜功能的影響.結果 隨著透析時間的延長,尿毒癥大鼠腹膜厚度增加,炎性細胞浸潤明顯,腹膜平衡試驗(PET)顯示超濾量明顯下降,葡萄糖轉運量上升,但塞來昔佈榦預組可提高超濾量,減少葡萄糖轉運量(P<0.05).5組動物的腹膜組織LVD及COX-2、VEGF-C、LYVE-1 mRNA和蛋白錶達的檢測髮現:與正常組相比,尿毒癥組和腹透組均明顯升高(P<0.05);而腹透+塞來昔佈榦預組較腹透組均明顯降低(P<0.05).相關性分析顯示,腹透組蛋白水平上COX-2的錶達量與LVD(r=0.847,P<0.05)、VEGF-C(r =0.910,P<0.05)呈正相關,VEGF-C的錶達量與LVD呈正相關(r=0.975,P<0.05).腹透+塞來昔佈榦預組蛋白水平上COX-2的錶達量與LVD(r=0.970,P<0.05)、VEGF-C(r =0.927,P<0.05)呈正相關,VEGF-C的錶達量與LVD呈正相關(r=0.919,P<0.05).結論 大鼠體內高糖透析液與尿毒癥環境的刺激可以促進腹膜組織COX-2、VEGF-C、LYVE-1基因和蛋白的錶達水平上調及新生淋巴管數量增多.COX-2抑製劑可緩解長期腹透導緻的腹膜組織形態結構和功能的改變,併能抑製新生淋巴管的形成,可能是通過COX-2依賴的途徑下調VEGF-C的產生而髮揮作用的.
목적 탐토배양합매-2 (COX-2)억제제(새래석포)대뇨독증복막투석(복투)대서복막림파관형성급복막공능적영향.방법 검측새래석포간예적뇨독증복투대서적복막,종복막적결구여공능、복막조직림파관밀도(LVD)급COX-2、혈관내피생장인자-C(VEGF-C)、림파관내피투명질산수체-1(LYVE-1)mRNA급단백표체수평,관찰새래석포대뇨독증복투대서복막림파관형성급복막공능적영향.결과 수착투석시간적연장,뇨독증대서복막후도증가,염성세포침윤명현,복막평형시험(PET)현시초려량명현하강,포도당전운량상승,단새래석포간예조가제고초려량,감소포도당전운량(P<0.05).5조동물적복막조직LVD급COX-2、VEGF-C、LYVE-1 mRNA화단백표체적검측발현:여정상조상비,뇨독증조화복투조균명현승고(P<0.05);이복투+새래석포간예조교복투조균명현강저(P<0.05).상관성분석현시,복투조단백수평상COX-2적표체량여LVD(r=0.847,P<0.05)、VEGF-C(r =0.910,P<0.05)정정상관,VEGF-C적표체량여LVD정정상관(r=0.975,P<0.05).복투+새래석포간예조단백수평상COX-2적표체량여LVD(r=0.970,P<0.05)、VEGF-C(r =0.927,P<0.05)정정상관,VEGF-C적표체량여LVD정정상관(r=0.919,P<0.05).결론 대서체내고당투석액여뇨독증배경적자격가이촉진복막조직COX-2、VEGF-C、LYVE-1기인화단백적표체수평상조급신생림파관수량증다.COX-2억제제가완해장기복투도치적복막조직형태결구화공능적개변,병능억제신생림파관적형성,가능시통과COX-2의뢰적도경하조VEGF-C적산생이발휘작용적.
Objective To investigate the effects of cyclooxygenase-2 (COX-2) inhibitor on peritoneal lymphangiogenesis and peritoneum function in uremic rat.Methods Uremic rats treated by peritoneal dialysis were intragastric administration celecoxib.Structures of peritoneum,peritoneal function,peritoneal lymphatic vessel density (LVD) were detected in every group.The mRNA of vascular endothelial growth factor-C (VEGF-C),lymphatic vessel endothelial hyluronan receptor-1 (LYVE-1) and COX-2 were tested by RT-PCR.The protein expressions of LYVE-1,VEGF-C,COX-2 were tested by western blot.Results With the extension of the duration of dialysis,the peritoneum thickness was increasing,inflammatory cell infiltrated obviously,uhrafiltration volume decreased significantly.But the celecoxib could increase uhrafiltration volume and reduce the glucose transport rate(P <0.05).Compared with the normal group,the levels of LVD,COX-2,VEGF-C,and LYVE-1 mRNA and protein were significantly up-regulated in uremic and dialysis groups (P <0.05).Compared with the uremic dialysis group,the levels of LVD,COX-2,VEGFC and LYVE-1 mRNA and protein were significantly down-regulated in the celecoxib group.There was a positive correlation between COX-2 and VEGF-C,LVD in protein levels,as well as VEGF-C and LVD (all P values < 0.05).Conclusions Hyper glucose dialysis solution and uremic condition could up-regulate the expression of COX-2,VEGF-C,LYVE-1 in gene and protein level and stimulate lymphangiogenesis.COX-2 inhibitor could delay the change of peritoneal structures and function.COX-2 inhibitor could prevem the lymphangiogenesis in uremic rat treated by peritoneal dialysis,which might down-regulate the expression of VEGF-C by COX-2 depended manner.